Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers

Oncology Reports

Volumn 23, Issue 2, 2010, Pages 299-305

  Mitra, A V ^a   Jameson, C ^b   Barbachano, Y ^b   Sodha, N ^a   Kote Jarai, Z ^a   Javed, A ^b   Bancroft, E ^b   Fletcher, A ^a   Cooper, C ^a   Peock, S ^c   Easton, D ^c   Eeles, R ^a,b   Foster, C S ^d  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b NATIONAL HEALTH SERVICE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Aggressive prostate cancer; BRCA germline mutations; Cell proliferation

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CELL PROLIFERATION; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HETEROZYGOTE DETECTION; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 76649099811     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000636     Document Type: Article

References (37)

1. Mitra A, Fisher G, Foster CS, et al: Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 98: 502-507, 2008.
2. Agalliu I, Gern R, Leanza S and Burk RD: Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res 15: 1112-1120, 2009.
3. Edwards SM, Kote-Jarai Z, Meitz J, et al: Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72: 1-12, 2003.
4. Narod SA, Neuhausen S, Vichodez G, et al: Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 99: 371-374, 2008.
5. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, et al: Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 99: 929-935, 2007.
6. Berney DM, Gopalan A, Kudahetti S, et al: Ki-67 and outcome in clinically localised prostate cancer: Analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 100: 888-893, 2009.
7. Foster CS, McLoughlin J, Bashir I and Abel PD: Markers of the metastatic phenotype in prostate cancer. Hum Path 23: 381-394, 1992.
8. McLoughlin J, Foster CS, Price P, WIlliams G and Abel PD: Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Br J Urol 72: 92-97, 1993.
9. Giusti RM, Rutter JL, Duray PH, et al: A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet 40: 787-792, 2003.
10. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62: 676-689, 1998.
11. Schluter C, Duchrow M, Wohlenberg C, et al: The cell proliferation-associated antigen of antobidy Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 123: 513-522, 1993.
12. Vincenz C and Kerppola TK: Different polycomb group CBX family proteins associate with distinct regions of chromatin using nonhomologous protein sequences. Proc Nat Acad Sci USA 105: 16572-16577, 2008.
13. Endl E and Gerdes J: The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 257: 231-237, 2000.
14. MacCallum DE and Hall PA: Biochemical characterization of pKi67 with the identification of a mitotic-specific form associated with hyperphosphorylation and altered DNA binding. Exp Cell Res 252: 186-198, 1999.
15. Fitzgibbons PL, Page DL, Weaver D, et al: Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 966-978, 2000.
16. Gerdes J, Lemke H, Baisch H, Walcker H, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
17. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000.
18. Philip J, Willmott S, Cornford P, et al: Analysis of potential biomarkers to enhance Gleason grading of prostate cancer. Br J Cancer (In press).
19. Pollack A, DeSilvio M, Khor LY, et al: Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation - Radiation Therapy Oncology Group Trial. J Clin Oncol 22: 2133-2140, 2004.
20. Jhavar S, Corbishley CM, Dearnaley D, et al: Construction of tissue microarrays from prostate needle biopsy specimens. Br J Cancer 93: 478-482, 2005.
21. Berney DM, Fisher G, Kattan MW, et al: Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. BJU Int 100: 1240-1244, 2007.
22. Deshmukh N and Foster CS: Grading prostate cancer. In: Pathology of the Prostate. Foster CS and Bostwick DG (eds). WB Saunders, Philadelphia, pp191-227, 1997.
23. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Der Pathologe 8: 138-140, 1987.
24. Khoo VS, Pollack A, Cowen D, et al: Relationship of Ki-67 labelling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate 41: 166-172, 1999.
25. Hall PA and Going JJ: Predicting the future: a critical appraisal of cancer prognosis studies. Histopathology 35: 489-494, 1999.
26. Feneley MR, Young MPA, Chinyama C, Kirby RS and Parkinson MC: Ki-67 expression in early prostate cancer and associated pathological lesions. J Clin Pathol 49: 741-748, 1996.
27. Brown DC and Gatter KC: Ki67 protein: the immaculate deception? Histopathology 40: 2-11, 2002.
28. Shaaban AM, Sloane JP, West CR and Foster CS: Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am J Pathol 160: 597-604, 2002.
29. Halvorsen OJ, Haukaas S, Hoisaeter PA and Akslen LA: Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. Anticancer Res 21: 4071-4076, 2001.
30. Mirtti T, Kallajoki M, Aaltonen M and Alanen K: Cyclin A and Ki-67 with DNA content in benign and malignant prostatic epithelial lesions. Anal Quant Cytol Histol 23: 229-237, 2001.
31. Dunsmuir WD, Gillett CE, Meyer LC, et al: Molecular markers for predicting prostate cancer stage and survival. Br J Urol Int 86: 869-878, 2000.
32. Cowen D, Troncoso P, Khoo VS, et al: Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res 8: 1148-1154, 2002.
33. Pollack A, Cowen D, Troncoso P, et al: Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax and bcl-x. Cancer 97: 1630-1638, 2003.
34. Petit T, Wilt M, Velten M, et al: Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40: 205-211, 2004.
35. Spyratos F, Ferrero-Pous M, Trassard M, et al: Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cut-off value. Cancer 94: 2151-2159, 2002.
36. Hall MJ, Reid JE, Burbidge LA, et al: BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer (In Press).
37. Kerner R, Sabo E, Gershoni-Baruch R, Beck D and Ben-Izhak O: Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology. Gynecol Oncol 99: 367-375, 2005.